New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:32 EDTCBST, SHPGCubist volatility expected to move on Shire rumored to weigh bid report
Cubist (CBST) option volatility is expected to move on Shire (SHPG) rumored to weigh a bid, FT Alphaville says. Overall option implied volatility of 41 is above its 26-week average of 38 according to Track Data, suggesting large price movement.
News For CBST;SHPG From The Last 14 Days
Check below for free stories on CBST;SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
11:26 EDTCBSTAmerican Society for Microbiology to hold a conference
Subscribe for More Information
August 31, 2014
14:04 EDTCBSTWorldwide Business Research to hold a conference
Subscribe for More Information
August 27, 2014
17:49 EDTSHPGGSK, Shire rumored to be interested in Tekmira, Daily Mail says
GlaxoSmithKline (GSK) and Shire (SHPG) are rumored to be interested in a bid for Tekmira (TKMR), reports Daily Mail. Tekmira could be a value to potential suitors, capitalized at approximately GBP 400M and the company could cost over GBP 1B in a takeover, Daily Mail adds. Reference Link
August 22, 2014
07:31 EDTCBSTCubist annouces EMA acceptance of ceftolozane, tazobactam MAA
Cubist announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane, tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, with a decision from the European Commission expected during 1H15. The MAA submission is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane, tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the EMA and U.S. Food and Drug Administration specified primary endpoints. Results of the secondary analyses were consistent with and supportive of the primary outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use